Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis

References

• World Health Organization. Global Report On Psoriasis. WHO Press: Geneva; 2016:1–48. Available from: https://apps.who.int/iris/bitstream/handle/10665/204417/9789241565189_eng.pdf?sequence=1&isAllowed=y. Accessed 236 2019.
   Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643–659. doi:10.1016/j.jaad.2008.12.03219217694
   PubMed Web of Science ®Google Scholar
• Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018. doi:10.1155/2012/56101823213332
   PubMed Web of Science ®Google Scholar
• Polistena B, Calzavara-Pinton P, Altomare G, et al. The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice. J Eur Acad Dermatol Venereol. 2015;29(12):2411–2416. doi:10.1111/jdv.1266926370321
   PubMed Web of Science ®Google Scholar
• Schadler ED, Ortel B, Mehlis SL. Biologics for the primary care physician: review and treatment of psoriasis. Dis Mon. 2019;65(3):51–90.30037762
   PubMed Web of Science ®Google Scholar
• Wang TS, Tsai TF. Managing scalp psoriasis: an evidence-based review. Am J Clin Dermatol. 2017;18(1):17–43.27650520
   PubMed Web of Science ®Google Scholar
• Guenther L. Current management of scalp psoriasis. Skin Therapy Lett. 2015;20(3):5–7.
   Google Scholar
• Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017;77(4):667–674.28780364
   PubMed Web of Science ®Google Scholar
• Globe D, Bayliss MS, Harrison DJ. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups. Health Qual Life Outcomes. 2009;7:62.19580674
   PubMed Web of Science ®Google Scholar
• Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. doi:10.1111/dth.1258929512290
   PubMed Web of Science ®Google Scholar
• Kromer C, Celis D, Sonntag D, Peitsch WK. Biologicals and small molecules in psoriasis: a systematic review of economic evaluations. PLoS One. 2018;13(1):e0189765. doi:10.1371/journal.pone.018976529298315
   PubMed Web of Science ®Google Scholar
• Frieder J, Kivelevitch D, Menter A. Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature. Ther Deliv. 2017;8(9):737–746. doi:10.4155/tde-2017-005828659016
   PubMed Web of Science ®Google Scholar
• Slominski AT, Kim TK, Takeda Y, et al. RORα and ROR γ are expressed in human skin and serve as receptors for endogenously produced noncalcemic 20-hydroxy- and 20,23-dihydroxyvitamin D. Faseb J. 2014;28(7):2775–2789. doi:10.1096/fj.13-24204024668754
   PubMed Web of Science ®Google Scholar
• Slominski AT, Kim TK, Janjetovic Z, et al. Differential and overlapping effects of 20,23(OH)₂D3 and 1,25(OH)₂D3 on gene expression in human epidermal keratinocytes: identification of ahr as an alternative receptor for 20,23(OH)₂D3. Int J Mol Sci. 2018;19(10):pii: E3072. doi:10.3390/ijms19103072
   Web of Science ®Google Scholar
• Cohen SN, Baron SE, Archer CB. British association of dermatologists and royal college of general practitioners. Guidance on the diagnosis and clinical management of psoriasis. Clin Exp Dermatol. 2012;37(Suppl 1):13–18. doi:10.1111/j.1365-2230.2012.04337.x22486764
   PubMed Web of Science ®Google Scholar
• Mason A, Mason J, Cork M, Hancock H, Dooley G. Topical treatments for chronic plaque psoriasis: an abridged cochrane systematic review. J Am Acad Dermatol. 2013;69(5):799–807. doi:10.1016/j.jaad.2013.06.02724124809
   PubMed Web of Science ®Google Scholar
• Gooderham M, Debarre JM, Keddy-Grant J, Xu Z, Kurvits M, Goodfield M. Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age. Br J Dermatol. 2014;171(6):1470–1477. doi:10.1111/bjd.1323524980277
   PubMed Web of Science ®Google Scholar
• Svendsen MT, Andersen F, Hansen J, Johannessen H, Andersen KE. Medical adherence to topical corticosteroid preparations prescribed for psoriasis: a systematic review. J Dermatolog Treat. 2017;28(1):32–39. doi:10.1080/09546634.2016.117837527151546
   PubMed Web of Science ®Google Scholar
• Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther (Heidelb). 2016;6(3):413–425. doi:10.1007/s13555-016-0125-627358072
   PubMed Web of Science ®Google Scholar
• Paul C, Bang B, Lebwohl M. Fixed combination calcipotriol plus betamethasone dipropionate aerosol foam in the treatment of psoriasis vulgaris: rationale for development and clinical profile. Expert Opin Pharmacother. 2017;18(1):115–121. doi:10.1080/14656566.2016.126974927936972
   PubMed Web of Science ®Google Scholar
• Girolomoni G, Calzavara Pinton P, Cristaudo A, Cicchetti A. Back to the future: a new topical approach for mild-to-moderate psoriasis. G Ital Dermatol Venereol. 2018;153(3):375–382.27982547
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Stein Gold L, Cambazard F, Kalb RE, Lowson D, Møller A, Paul C. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. Eur J Dermatol. 2018;28(3):356–363.29952297
   PubMed Web of Science ®Google Scholar
• Vender R, Gooderham MJ, Guenther LC, et al. Psoriasis patients’ preference for an aerosol foam topical formulation. J Eur Acad Dermatol Venereol. 2018;32(11):e400–401. doi:10.1111/jdv.1428229633366
   PubMed Web of Science ®Google Scholar
• Pinter A, Thormann H, Angeletti F, Jalili A. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. Clin Cosmet Investig Dermatol. 2018;11:451–459. doi:10.2147/CCID.S180698
   PubMed Web of Science ®Google Scholar
• Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008;59(3):455–463. doi:10.1016/j.jaad.2008.04.02718694678
   PubMed Web of Science ®Google Scholar
• van de Kerkhof PCM, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol. 2009;160(1):170–176. doi:10.1111/j.1365-2133.2008.08927.x19067709
   PubMed Web of Science ®Google Scholar
• Tyring S, Mendoza N, Appell M, et al. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol. 2010;49(11):1328–1333. doi:10.1111/j.1365-4632.2010.04598.x20964660
   PubMed Web of Science ®Google Scholar
• Kragballe K, Hoffmann V, Ortonne JP, Tan J, Nordin P, Segaert S. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol. 2009;161(1):159–166. doi:10.1111/j.1365-2133.2009.09116.x19416259
   PubMed Web of Science ®Google Scholar
• Ma L, Yang Q, Yang H, et al. Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population. Int J Dermatol. 2016;55(1):106–113. doi:10.1111/ijd.1314526094549
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Tyring S, Bukhalo M, et al. Fixed combination aerosol foam calcipotriene 0.005% (Cal) plus betamethasone dipropionate 0.064% (BD) is more efficacious than Cal or BD aerosol foam alone for psoriasis vulgaris: a randomized, double-blind, multicenter, three-arm, phase 2 study. J Clin Aesthet Dermatol. 2016;9(2):34–41.
   PubMedGoogle Scholar
• Patel DS, Veverka KA, Nyeland ME, Yamauchi PS, Alonso-Llamazares J, Lebwohl M. Improvements In Efficacy And Lesion Quality In Scalp Plaque Psoriasis With Fixed Combination Calcipotriene And Betamethasone Dipropionate (cal/bd) Foam Treatment [abstract/poster No. 9803]. American Academy of Dermatology Annual Meeting: Washington, DC, USA; 2019 1–53 2019.
   Google Scholar
• Mason KJ, Barker JNWN, Smith CH, et al. Comparison of drug discontinuation, effectiveness, and safety between clinical trial eligible and ineligible patients in BADBIR. JAMA Dermatol. 2018;154(5):581–588. doi:10.1001/jamadermatol.2017.619529590279
   PubMed Web of Science ®Google Scholar